Delamanid for Rifampicin – Resistant Tuberculosis : A Retrospective Study from South Africa

This study describes early efficacy and safety from a programmatic setting in South Africa

From:
Department for International Development
Published
14 June 2018
Country:
South Africa
Document Type:
Journal Article
Theme:
Health
Authors:
Mohr, E, Hughes, J, Reuter, A, Duran, L.T.

Abstract

Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. This study describes early efficacy and safety from a programmatic setting in South Africa.

This was a retrospective cohort study of patients receiving Dlm-containing treatment regimens between November 2015 and August 2017.

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Mohr E, Hughes J, Reuter A, Duran LT, Ferlazzo G, Daniels J, Avezedo V De, Kock Y, Steele SJ, Shroufi A, Ade S, Alikhanova N, Benedetti G, Edwards J, Cox H, Furin J, Isaakidis P. Delamanid for Rifampicin – Resistant Tuberculosis : A Retrospective Study from South Africa. Eur. Respir. J. [Internet]. 2018;51(6):1800017. Available from: http://erj.ersjournals.com/content/early/2018/04/26/13993003.00017-2018

Delamanid for Rifampicin – Resistant Tuberculosis : A Retrospective Study from South Africa

Updates to this page

Published 14 June 2018
Contents